262 related articles for article (PubMed ID: 32088843)
1. Evaluation of the INCREMENT-CPE, Pitt Bacteremia and qPitt Scores in Patients with Carbapenem-Resistant Enterobacteriaceae Infections Treated with Ceftazidime-Avibactam.
Jorgensen SCJ; Trinh TD; Zasowski EJ; Lagnf AM; Bhatia S; Melvin SM; Simon SP; Rosenberg JR; Steed ME; Estrada SJ; Morrisette T; Davis SL; Rybak MJ
Infect Dis Ther; 2020 Jun; 9(2):291-304. PubMed ID: 32088843
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of ceftazidime-avibactam versus colistin in treating carbapenem-resistant Enterobacteriaceae bacteremia.
Hakeam HA; Alsahli H; Albabtain L; Alassaf S; Al Duhailib Z; Althawadi S
Int J Infect Dis; 2021 Aug; 109():1-7. PubMed ID: 34091006
[TBL] [Abstract][Full Text] [Related]
3. The Pitt Bacteremia Score Predicts Mortality in Nonbacteremic Infections.
Henderson H; Luterbach CL; Cober E; Richter SS; Salata RA; Kalayjian RC; Watkins RR; Doi Y; Kaye KS; Evans S; Fowler VG; Bonomo RA; Harris A; Napravnik S; Van Duin D
Clin Infect Dis; 2020 Apr; 70(9):1826-1833. PubMed ID: 31219148
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients.
Castón JJ; Lacort-Peralta I; Martín-Dávila P; Loeches B; Tabares S; Temkin L; Torre-Cisneros J; Paño-Pardo JR
Int J Infect Dis; 2017 Jun; 59():118-123. PubMed ID: 28392315
[TBL] [Abstract][Full Text] [Related]
5. Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant
Ackley R; Roshdy D; Meredith J; Minor S; Anderson WE; Capraro GA; Polk C
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094128
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and mortality of ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae bloodstream infections (2018-2022).
Boattini M; Bianco G; Bastos P; Comini S; Corcione S; Almeida A; Costa C; De Rosa FG; Cavallo R
Eur J Clin Microbiol Infect Dis; 2024 Jan; 43(1):155-166. PubMed ID: 37985552
[TBL] [Abstract][Full Text] [Related]
7. Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae.
van Duin D; Lok JJ; Earley M; Cober E; Richter SS; Perez F; Salata RA; Kalayjian RC; Watkins RR; Doi Y; Kaye KS; Fowler VG; Paterson DL; Bonomo RA; Evans S;
Clin Infect Dis; 2018 Jan; 66(2):163-171. PubMed ID: 29020404
[TBL] [Abstract][Full Text] [Related]
8. Impact of ceftazidime/avibactam versus best available therapy on mortality from infections caused by carbapenemase-producing Enterobacterales (CAVICOR study).
Castón JJ; Cano A; Pérez-Camacho I; Aguado JM; Carratalá J; Ramasco F; Soriano A; Pintado V; Castelo-Corral L; Sousa A; Fariñas MC; Muñoz P; Abril López De Medrano V; Sanz-Peláez Ó; Los-Arcos I; Gracia-Ahufinger I; Pérez-Nadales E; Vidal E; Doblas A; Natera C; Martínez-Martínez L; Torre-Cisneros J
J Antimicrob Chemother; 2022 Apr; 77(5):1452-1460. PubMed ID: 35187577
[TBL] [Abstract][Full Text] [Related]
9. Clinical Outcomes in Carbapenem-Resistant Enterobacteriaceae Infections Treated With Ceftazidime-Avibactam: A Single-Center Observational Study.
Rathish B; Wilson A; Warrier A; Prakash S; Babu R; Joy S
Cureus; 2021 Feb; 13(2):e13081. PubMed ID: 33680621
[TBL] [Abstract][Full Text] [Related]
10. Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections.
Shields RK; Nguyen MH; Chen L; Press EG; Kreiswirth BN; Clancy CJ
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29507064
[TBL] [Abstract][Full Text] [Related]
11. Ceftazidime-avibactam with or without Aztreonam vs Polymyxin-based Combination Therapy for Carbapenem-resistant Enterobacteriaceae: A Retrospective Analysis.
Prayag PS; Patwardhan SA; Panchakshari S; Sambasivam R; Dhupad S; Soman RN; Prayag AP
Indian J Crit Care Med; 2023 Jun; 27(6):444-450. PubMed ID: 37378372
[TBL] [Abstract][Full Text] [Related]
12. Prediction of 30-Day Mortality Using the Quick Pitt Bacteremia Score in Hospitalized Patients with
Su C; Tsai IT; Lai CH; Lin KH; Chen CC; Hsu YC
Infect Drug Resist; 2023; 16():4807-4815. PubMed ID: 37520452
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae.
Alraddadi BM; Saeedi M; Qutub M; Alshukairi A; Hassanien A; Wali G
BMC Infect Dis; 2019 Sep; 19(1):772. PubMed ID: 31484510
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam.
De la Calle C; Rodríguez O; Morata L; Marco F; Cardozo C; García-Vidal C; Río AD; Feher C; Pellicé M; Puerta-Alcalde P; Mensa J; Soriano A; Martínez JA
Int J Antimicrob Agents; 2019 Apr; 53(4):520-524. PubMed ID: 30471403
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of ceftazidime/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae.
Sousa A; Pérez-Rodríguez MT; Soto A; Rodríguez L; Pérez-Landeiro A; Martínez-Lamas L; Nodar A; Crespo M
J Antimicrob Chemother; 2018 Nov; 73(11):3170-3175. PubMed ID: 30099490
[TBL] [Abstract][Full Text] [Related]
16. Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae.
Santevecchi BA; Smith TT; MacVane SH
Int J Antimicrob Agents; 2018 Apr; 51(4):629-635. PubMed ID: 29408227
[TBL] [Abstract][Full Text] [Related]
17. Acute kidney injury should not be neglected - optimization of quick Pitt bacteremia score for predicting mortality in critically ill patients with bloodstream infection: a retrospective cohort study.
Cai J; Yang M; Deng H; Bai H; Zheng G; He J
Ther Adv Infect Dis; 2024; 11():20499361241231147. PubMed ID: 38410828
[TBL] [Abstract][Full Text] [Related]
18. The Comparative Efficacy of Ceftazidime-Avibactam with or without Aztreonam vs Polymyxins for Carbapenem-resistant Enterobacteriaceae Infections: A Prospective Observational Cohort Study.
Vijayakumar M; Selvam V; Renuka MK; Rajagopalan RE
Indian J Crit Care Med; 2023 Dec; 27(12):923-929. PubMed ID: 38074953
[TBL] [Abstract][Full Text] [Related]
19. Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections.
King M; Heil E; Kuriakose S; Bias T; Huang V; El-Beyrouty C; McCoy D; Hiles J; Richards L; Gardner J; Harrington N; Biason K; Gallagher JC
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28483952
[TBL] [Abstract][Full Text] [Related]
20. Impact of a Rapid Molecular Test for Klebsiella pneumoniae Carbapenemase and Ceftazidime-Avibactam Use on Outcomes After Bacteremia Caused by Carbapenem-Resistant Enterobacterales.
Satlin MJ; Chen L; Gomez-Simmonds A; Marino J; Weston G; Bhowmick T; Seo SK; Sperber SJ; Kim AC; Eilertson B; Derti S; Jenkins SG; Levi MH; Weinstein MP; Tang YW; Hong T; Juretschko S; Hoffman KL; Walsh TJ; Westblade LF; Uhlemann AC; Kreiswirth BN
Clin Infect Dis; 2022 Dec; 75(12):2066-2075. PubMed ID: 35522019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
